

23 Apr 2018 | News

QUOTED. April 23, 2018. Larry Biegelsen.

by

Check out what Wells Fargo analyst Larry Biegelsen had to say about why a global patent battle between Edwards Lifesciences and Boston Scientific on transcatheter aortic valve replacements will likely end in settlement.

"[Boston Scientific] appears to have the upper hand in Europe (at least at the moment), while [Edwards] appears to have a position of strength in the US based on the favorable IPR decision against BSX's '608 patent this past March." – Larry Biegelsen, senior medical device analyst, Wells Fargo

- Find out more: [Boston Sci Wins Latest TAVR Patent Dispute Against Edwards](#)

[Click here](#) for a free trial of *Medtech Insight*